ViewRay Demonstrates Potential Therapy Applications for MRI-Guided Radiation at ASTRO 2011
Company's Development of Integrated Medical Imaging and Radiation Therapy Technology Progresses
CLEVELAND, Sept. 29, 2011
CLEVELAND, Sept. 29, 2011 /PRNewswire/ -- ViewRay™, Inc., a privately held medical device company, will present potential applications for MRI-guided radiotherapy at the annual meeting of the American Society for Radiation Oncology (ASTRO) October 2 – 4 in Miami Beach, Florida, with software demonstrations in booth #865. The company's new research radiation therapy system is being developed to feature a patented combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI). The system is being designed to let radiation oncologists see what they're treating, while they're treating.
Visitors to ViewRay's ASTRO booth can view software demonstrations and learn about the key capabilities being designed into the system. In addition to quality pretreatment imaging and advanced treatment delivery, the ViewRay system is being developed to enable:
On-table dose prediction — fast dose prediction using volumetric image data captured just prior to treatment.
Soft-tissue targeting — continuous, MRI-guided tracking of soft tissues and automatic beam control for real-time adaptation to motion.
Adaptive optimization — fast, convenient reoptimization for effective online and offline plan adaptation.
Review and assessment — software tools that help physicians better understand and manage the progress of treatment.
ViewRay holds the exclusive worldwide license for its combination of MRI and radiation therapy technologies. Earlier this year, landmark patents were issued for ViewRay's core technology in both the United States and Europe. ViewRay's treatment planning and delivery software recently received 510(k) premarket notification clearance from the U.S. FDA, and its integrated imaging and radiotherapy delivery system is now pending 510(k) review. The ViewRay system is currently available only as a non–human use research system.
"With the 510(k) clearance of our software, the issuance of patents on our technology, and the addition of several new research partners, we've reached major milestones this year," said ViewRay President and CEO Gregory M. Ayers, MD, PhD. "We're looking forward to sharing our progress with the ASTRO community." ViewRay research partners now include the University of California, Los Angeles (UCLA) Health System – Jonsson Comprehensive Cancer Center, the University of Wisconsin Carbone Cancer Center, and the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine, where the first ViewRay research system is currently being installed.
ViewRay, Inc., of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system is being designed to provide continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.
ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.